ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

ClinicalTrials.gov ID: NCT06811116

Public ClinicalTrials.gov record NCT06811116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

Study identification

NCT ID
NCT06811116
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
92 participants

Conditions and interventions

Interventions

  • Biospecimen Collection Procedure
  • Cabozantinib S-malate Drug
  • Imaging Procedure Procedure
  • Sapanisertib Drug

Procedure · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2025
Primary completion
Aug 30, 2027
Completion
Aug 30, 2027
Last update posted
Apr 12, 2026

2025 – 2027

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine California 92612 Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868 Recruiting
Oregon Health and Science University Portland Oregon 97239 Recruiting
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06811116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06811116 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →